Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.39 |
| ▸ | CD44 | P16070 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16916827 | 0.85 | PNMT (0.39) | PNMTHTR2AHTR2CHTR2BADRA2A | |
| SCHEMBL7935912 | 0.81 | PNMT (0.42) | PNMTPARP1TNKS2PARP2HTR2A | |
| SCHEMBL5769370 | 0.81 | CD44 (0.35) | PNMTCD44PARP1TNKS2PARP2 | |
| Hydrochloric Acid SCHEMBL21753155 | 0.79 | PNMT (0.41) | PNMTPARP1TNKS2PARP2HTR2A | |
| SCHEMBL31536283 | 0.78 | PNMT (0.39) | PNMTPARP1TNKS2PARP2HTR2A | |
| SCHEMBL15859963 | 0.78 | HTR2A (0.39) | PNMTCD44PARP1TNKS2PARP2 | |
| SCHEMBL9269307 | 0.72 | ACHE (0.52) | ADRA2A | |
| SCHEMBL9267023 | 0.72 | ACHE (0.50) | ADRA2A | |
| SCHEMBL11288061 | 0.71 | ACHE (0.50) | ADRA2A | |
| SCHEMBL16916256 | 0.69 | NNMT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023033742-A1 | COMPOUNDS USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2023-03-09 | — | — | WO | disclosed |
| CN-106458996-B | Fused pyrimidines as inhibitors of the p97 complex | 克里弗生物科学公司 | 2020-11-03 | — | — | CN | disclosed |
| EP-3097092-B1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-9828363-B2 | Fused pyrimidines as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| WO-2016200840-A1 | MONO AND BICYCLIC RING BORONIC ACID, ESTER AND SALT COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| EP-3097092-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| WO-2015109285-A1 | FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2015-07-23 | — | — | WO | disclosed |
| WO-2010014939-A1 | PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174005-B2 | Fused pyrimidines as inhibitors of p97 complex | WDR77, POP1, PSMG3 | PNMT 3575/4885CD44 4171/4885PARP1 2231/4885 |
| US-20160332990-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | PNMT 3575/4885CD44 4171/4885PARP1 2231/4885 |
| US-20180044325-A1 | FUSED PYRIMIDINES AS INHIBITORS OF P97 COMPLEX | WDR77, POP1, PSMG3 | PNMT 3566/4885CD44 4182/4885PARP1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.